Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD, MAD, and Food Effect Study of JX09 in Healthy Adults
NCT06183671Phase 1Completed
- Sponsor
- JIXING
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JX09 in resistant hypertension (RH) (3 arms), sponsored by JIXING. Primary endpoints: Incidence of adverse events and serious adverse events at 26 days, Clinically significant change from baseline in physical examinations at 26 days and 3 more. Started Jan 2024; status: completed.
02
Drugs
JX09
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT06183671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06183671.